In this study we have used the hypoxia-targeting MRI contrast agent GdDO3NI, (a nitroimidazole-based T1 contrast agent) to image the development of hypoxia in two types of rodent brain tumor models. Our results indicate a range of signal enhancements from 0-17% over baseline in the C6 and 9L tumors using GdDO3NI with clearance from contralateral brain and muscle tissue. This study further demonstrates the utility of GdDO3NI in non-invasive imaging of tissue hypoxia with high resolution.
This abstract and the presentation materials are available to members only; a login is required.